Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mouse: a model mimicking inflammatory bowel disease
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mouse : a model mimicking inflammatory bowel disease. / Holgersen, Kristine; Kvist, Peter Helding ; Markholst, Helle; Hansen, Axel Jacob Kornerup; Holm, Thomas Lindebo.
In: Journal of Crohn's and Colitis, Vol. 8, No. 2, 2014, p. 147-160.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mouse
T2 - a model mimicking inflammatory bowel disease
AU - Holgersen, Kristine
AU - Kvist, Peter Helding
AU - Markholst, Helle
AU - Hansen, Axel Jacob Kornerup
AU - Holm, Thomas Lindebo
PY - 2014
Y1 - 2014
N2 - Background: In inflammatory bowel disease a defective mucosal barrier, a dysregulated immune response and an excessive reactivity against the gut microbiota are assumed to cause a breakdown of the intestinal homeostasis and lead to chronic inflammation. Piroxicam treatment is a method for induction of colitis in IL-10 k.o. mice, which integrates a dysfunction of both the intestinal barrier and the immune system. However, the translational value of this model has not been thoroughly clarified. Aim: To characterise the piroxicam-accelerated colitis (PAC) IL-10 k.o. model with respect to clinical features, pathogenic mechanisms and its ability to respond to existing therapies. Methods: The PAC IL-10 k.o. model was established on a C57BL/6 J background and the clinical manifestations, immunological mechanisms and efficacy of ampicillin and anti-IL-12/23p40 treatment were assessed.
AB - Background: In inflammatory bowel disease a defective mucosal barrier, a dysregulated immune response and an excessive reactivity against the gut microbiota are assumed to cause a breakdown of the intestinal homeostasis and lead to chronic inflammation. Piroxicam treatment is a method for induction of colitis in IL-10 k.o. mice, which integrates a dysfunction of both the intestinal barrier and the immune system. However, the translational value of this model has not been thoroughly clarified. Aim: To characterise the piroxicam-accelerated colitis (PAC) IL-10 k.o. model with respect to clinical features, pathogenic mechanisms and its ability to respond to existing therapies. Methods: The PAC IL-10 k.o. model was established on a C57BL/6 J background and the clinical manifestations, immunological mechanisms and efficacy of ampicillin and anti-IL-12/23p40 treatment were assessed.
KW - Faculty of Health and Medical Sciences
KW - Inflammatory bowel disease
KW - Crohn's disease
KW - Interleukin-10 knock out mouse
KW - Piroxicam
U2 - 10.1016/j.crohns.2013.08.002
DO - 10.1016/j.crohns.2013.08.002
M3 - Journal article
C2 - 23994255
VL - 8
SP - 147
EP - 160
JO - Journal of Crohn's and Colitis
JF - Journal of Crohn's and Colitis
SN - 1873-9946
IS - 2
ER -
ID: 68162694